Loading…
New and emerging targeted therapies for cystic fibrosis
Cystic fibrosis (CF) is a monogenic autosomal recessive disorder that affects about 70 000 people worldwide. The clinical manifestations of the disease are caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The discovery of the CFTR gene in 1989 has led to a...
Saved in:
Published in: | BMJ (Online) 2016-03, Vol.352, p.i859-i859 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-b428t-f7c5fa484653af1ec7656bb6fa36dd8c56d2062c05468e8e55b388e3c5240e2a3 |
---|---|
cites | |
container_end_page | i859 |
container_issue | |
container_start_page | i859 |
container_title | BMJ (Online) |
container_volume | 352 |
creator | Quon, Bradley S Rowe, Steven M |
description | Cystic fibrosis (CF) is a monogenic autosomal recessive disorder that affects about 70 000 people worldwide. The clinical manifestations of the disease are caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The discovery of the CFTR gene in 1989 has led to a sophisticated understanding of how thousands of mutations in the CFTR gene affect the structure and function of the CFTR protein. Much progress has been made over the past decade with the development of orally bioavailable small molecule drugs that target defective CFTR proteins caused by specific mutations. Furthermore, there is considerable optimism about the prospect of gene replacement or editing therapies to correct all mutations in cystic fibrosis. The recent approvals of ivacaftor and lumacaftor represent the genesis of a new era of precision medicine in the treatment of this condition. These drugs are having a positive impact on the lives of people with cystic fibrosis and are potentially disease modifying. This review provides an update on advances in our understanding of the structure and function of the CFTR, with a focus on state of the art targeted drugs that are in development. |
doi_str_mv | 10.1136/bmj.i859 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4817245</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008212051</sourcerecordid><originalsourceid>FETCH-LOGICAL-b428t-f7c5fa484653af1ec7656bb6fa36dd8c56d2062c05468e8e55b388e3c5240e2a3</originalsourceid><addsrcrecordid>eNp1kVtLwzAYhoMobsyBv0AK3njTmUNz2I0gwxMMvdHrkKZfu4weZtIq-_d2OucUvEogT558eV-ETgmeEMLEZVotJ07x6QEaEslFTBRjh3v7ARqHsMQYUybVVPBjNKASMywkHyL5CO-RqbMIKvCFq4uoNb6AFrKoXYA3Kwchyhsf2XVonY1yl_omuHCCjnJTBhhv1xF6ub15nt3H86e7h9n1PE4Tqto4l5bnJlGJ4MzkBKwUXKSpyA0TWaYsFxnFglrME6FAAecpUwqY5TTBQA0boasv76pLK8gs1K03pV55Vxm_1o1x-vdJ7Ra6aN50ooikCe8FF1uBb147CK2uXLBQlqaGpguaSCmnSiQY9-j5H3TZdL7uv_dJ9VESoX6Etg8ieMh3wxCsN4XovhC9KaRHz_aH34Hf8f-8uLnyr-YDQN2RjA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777833168</pqid></control><display><type>article</type><title>New and emerging targeted therapies for cystic fibrosis</title><source>BMJ</source><source>JSTOR Archival Journals and Primary Sources Collection</source><creator>Quon, Bradley S ; Rowe, Steven M</creator><creatorcontrib>Quon, Bradley S ; Rowe, Steven M</creatorcontrib><description>Cystic fibrosis (CF) is a monogenic autosomal recessive disorder that affects about 70 000 people worldwide. The clinical manifestations of the disease are caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The discovery of the CFTR gene in 1989 has led to a sophisticated understanding of how thousands of mutations in the CFTR gene affect the structure and function of the CFTR protein. Much progress has been made over the past decade with the development of orally bioavailable small molecule drugs that target defective CFTR proteins caused by specific mutations. Furthermore, there is considerable optimism about the prospect of gene replacement or editing therapies to correct all mutations in cystic fibrosis. The recent approvals of ivacaftor and lumacaftor represent the genesis of a new era of precision medicine in the treatment of this condition. These drugs are having a positive impact on the lives of people with cystic fibrosis and are potentially disease modifying. This review provides an update on advances in our understanding of the structure and function of the CFTR, with a focus on state of the art targeted drugs that are in development.</description><identifier>ISSN: 1756-1833</identifier><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1756-1833</identifier><identifier>DOI: 10.1136/bmj.i859</identifier><identifier>PMID: 27030675</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Aminophenols - therapeutic use ; Aminopyridines - therapeutic use ; Antibiotics ; Bacterial infections ; Benzodioxoles - therapeutic use ; Clinical Review ; Clinical Trials as Topic ; Cystic fibrosis ; Cystic Fibrosis - genetics ; Cystic Fibrosis - therapy ; Cystic Fibrosis Transmembrane Conductance Regulator - drug effects ; Cystic Fibrosis Transmembrane Conductance Regulator - genetics ; Cystic Fibrosis Transmembrane Conductance Regulator - physiology ; Drug Discovery - trends ; Drug Therapy, Combination ; Enzymes ; Forced Expiratory Volume - drug effects ; Forecasting ; Genes ; Genetic Therapy - methods ; Genetic Therapy - trends ; Homozygote ; Humans ; Inflammation ; Kinases ; Molecular Targeted Therapy - methods ; Molecular Targeted Therapy - trends ; Mutation ; Mutation - genetics ; Nitric oxide ; Oxadiazoles - therapeutic use ; Phosphodiesterase 5 Inhibitors - therapeutic use ; Practice Guidelines as Topic ; Precision Medicine - methods ; Precision Medicine - trends ; Proteins ; Quinolones - therapeutic use</subject><ispartof>BMJ (Online), 2016-03, Vol.352, p.i859-i859</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Copyright BMJ Publishing Group LTD Mar 30, 2016</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to 2016 BMJ</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b428t-f7c5fa484653af1ec7656bb6fa36dd8c56d2062c05468e8e55b388e3c5240e2a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://bmj.com/content/352/bmj.i859.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://bmj.com/content/352/bmj.i859.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>112,113,230,313,314,780,784,792,885,3192,27920,27922,27923,77364,77365</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27030675$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Quon, Bradley S</creatorcontrib><creatorcontrib>Rowe, Steven M</creatorcontrib><title>New and emerging targeted therapies for cystic fibrosis</title><title>BMJ (Online)</title><addtitle>BMJ</addtitle><description>Cystic fibrosis (CF) is a monogenic autosomal recessive disorder that affects about 70 000 people worldwide. The clinical manifestations of the disease are caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The discovery of the CFTR gene in 1989 has led to a sophisticated understanding of how thousands of mutations in the CFTR gene affect the structure and function of the CFTR protein. Much progress has been made over the past decade with the development of orally bioavailable small molecule drugs that target defective CFTR proteins caused by specific mutations. Furthermore, there is considerable optimism about the prospect of gene replacement or editing therapies to correct all mutations in cystic fibrosis. The recent approvals of ivacaftor and lumacaftor represent the genesis of a new era of precision medicine in the treatment of this condition. These drugs are having a positive impact on the lives of people with cystic fibrosis and are potentially disease modifying. This review provides an update on advances in our understanding of the structure and function of the CFTR, with a focus on state of the art targeted drugs that are in development.</description><subject>Aminophenols - therapeutic use</subject><subject>Aminopyridines - therapeutic use</subject><subject>Antibiotics</subject><subject>Bacterial infections</subject><subject>Benzodioxoles - therapeutic use</subject><subject>Clinical Review</subject><subject>Clinical Trials as Topic</subject><subject>Cystic fibrosis</subject><subject>Cystic Fibrosis - genetics</subject><subject>Cystic Fibrosis - therapy</subject><subject>Cystic Fibrosis Transmembrane Conductance Regulator - drug effects</subject><subject>Cystic Fibrosis Transmembrane Conductance Regulator - genetics</subject><subject>Cystic Fibrosis Transmembrane Conductance Regulator - physiology</subject><subject>Drug Discovery - trends</subject><subject>Drug Therapy, Combination</subject><subject>Enzymes</subject><subject>Forced Expiratory Volume - drug effects</subject><subject>Forecasting</subject><subject>Genes</subject><subject>Genetic Therapy - methods</subject><subject>Genetic Therapy - trends</subject><subject>Homozygote</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Kinases</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Molecular Targeted Therapy - trends</subject><subject>Mutation</subject><subject>Mutation - genetics</subject><subject>Nitric oxide</subject><subject>Oxadiazoles - therapeutic use</subject><subject>Phosphodiesterase 5 Inhibitors - therapeutic use</subject><subject>Practice Guidelines as Topic</subject><subject>Precision Medicine - methods</subject><subject>Precision Medicine - trends</subject><subject>Proteins</subject><subject>Quinolones - therapeutic use</subject><issn>1756-1833</issn><issn>0959-8138</issn><issn>1756-1833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp1kVtLwzAYhoMobsyBv0AK3njTmUNz2I0gwxMMvdHrkKZfu4weZtIq-_d2OucUvEogT558eV-ETgmeEMLEZVotJ07x6QEaEslFTBRjh3v7ARqHsMQYUybVVPBjNKASMywkHyL5CO-RqbMIKvCFq4uoNb6AFrKoXYA3Kwchyhsf2XVonY1yl_omuHCCjnJTBhhv1xF6ub15nt3H86e7h9n1PE4Tqto4l5bnJlGJ4MzkBKwUXKSpyA0TWaYsFxnFglrME6FAAecpUwqY5TTBQA0boasv76pLK8gs1K03pV55Vxm_1o1x-vdJ7Ra6aN50ooikCe8FF1uBb147CK2uXLBQlqaGpguaSCmnSiQY9-j5H3TZdL7uv_dJ9VESoX6Etg8ieMh3wxCsN4XovhC9KaRHz_aH34Hf8f-8uLnyr-YDQN2RjA</recordid><startdate>20160330</startdate><enddate>20160330</enddate><creator>Quon, Bradley S</creator><creator>Rowe, Steven M</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160330</creationdate><title>New and emerging targeted therapies for cystic fibrosis</title><author>Quon, Bradley S ; Rowe, Steven M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b428t-f7c5fa484653af1ec7656bb6fa36dd8c56d2062c05468e8e55b388e3c5240e2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aminophenols - therapeutic use</topic><topic>Aminopyridines - therapeutic use</topic><topic>Antibiotics</topic><topic>Bacterial infections</topic><topic>Benzodioxoles - therapeutic use</topic><topic>Clinical Review</topic><topic>Clinical Trials as Topic</topic><topic>Cystic fibrosis</topic><topic>Cystic Fibrosis - genetics</topic><topic>Cystic Fibrosis - therapy</topic><topic>Cystic Fibrosis Transmembrane Conductance Regulator - drug effects</topic><topic>Cystic Fibrosis Transmembrane Conductance Regulator - genetics</topic><topic>Cystic Fibrosis Transmembrane Conductance Regulator - physiology</topic><topic>Drug Discovery - trends</topic><topic>Drug Therapy, Combination</topic><topic>Enzymes</topic><topic>Forced Expiratory Volume - drug effects</topic><topic>Forecasting</topic><topic>Genes</topic><topic>Genetic Therapy - methods</topic><topic>Genetic Therapy - trends</topic><topic>Homozygote</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Kinases</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Molecular Targeted Therapy - trends</topic><topic>Mutation</topic><topic>Mutation - genetics</topic><topic>Nitric oxide</topic><topic>Oxadiazoles - therapeutic use</topic><topic>Phosphodiesterase 5 Inhibitors - therapeutic use</topic><topic>Practice Guidelines as Topic</topic><topic>Precision Medicine - methods</topic><topic>Precision Medicine - trends</topic><topic>Proteins</topic><topic>Quinolones - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Quon, Bradley S</creatorcontrib><creatorcontrib>Rowe, Steven M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection (ProQuest Medical & Health Databases)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest research library</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ (Online)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Quon, Bradley S</au><au>Rowe, Steven M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New and emerging targeted therapies for cystic fibrosis</atitle><jtitle>BMJ (Online)</jtitle><addtitle>BMJ</addtitle><date>2016-03-30</date><risdate>2016</risdate><volume>352</volume><spage>i859</spage><epage>i859</epage><pages>i859-i859</pages><issn>1756-1833</issn><issn>0959-8138</issn><eissn>1756-1833</eissn><abstract>Cystic fibrosis (CF) is a monogenic autosomal recessive disorder that affects about 70 000 people worldwide. The clinical manifestations of the disease are caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The discovery of the CFTR gene in 1989 has led to a sophisticated understanding of how thousands of mutations in the CFTR gene affect the structure and function of the CFTR protein. Much progress has been made over the past decade with the development of orally bioavailable small molecule drugs that target defective CFTR proteins caused by specific mutations. Furthermore, there is considerable optimism about the prospect of gene replacement or editing therapies to correct all mutations in cystic fibrosis. The recent approvals of ivacaftor and lumacaftor represent the genesis of a new era of precision medicine in the treatment of this condition. These drugs are having a positive impact on the lives of people with cystic fibrosis and are potentially disease modifying. This review provides an update on advances in our understanding of the structure and function of the CFTR, with a focus on state of the art targeted drugs that are in development.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>27030675</pmid><doi>10.1136/bmj.i859</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1756-1833 |
ispartof | BMJ (Online), 2016-03, Vol.352, p.i859-i859 |
issn | 1756-1833 0959-8138 1756-1833 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4817245 |
source | BMJ; JSTOR Archival Journals and Primary Sources Collection |
subjects | Aminophenols - therapeutic use Aminopyridines - therapeutic use Antibiotics Bacterial infections Benzodioxoles - therapeutic use Clinical Review Clinical Trials as Topic Cystic fibrosis Cystic Fibrosis - genetics Cystic Fibrosis - therapy Cystic Fibrosis Transmembrane Conductance Regulator - drug effects Cystic Fibrosis Transmembrane Conductance Regulator - genetics Cystic Fibrosis Transmembrane Conductance Regulator - physiology Drug Discovery - trends Drug Therapy, Combination Enzymes Forced Expiratory Volume - drug effects Forecasting Genes Genetic Therapy - methods Genetic Therapy - trends Homozygote Humans Inflammation Kinases Molecular Targeted Therapy - methods Molecular Targeted Therapy - trends Mutation Mutation - genetics Nitric oxide Oxadiazoles - therapeutic use Phosphodiesterase 5 Inhibitors - therapeutic use Practice Guidelines as Topic Precision Medicine - methods Precision Medicine - trends Proteins Quinolones - therapeutic use |
title | New and emerging targeted therapies for cystic fibrosis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T11%3A02%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20and%20emerging%20targeted%20therapies%20for%20cystic%20fibrosis&rft.jtitle=BMJ%20(Online)&rft.au=Quon,%20Bradley%20S&rft.date=2016-03-30&rft.volume=352&rft.spage=i859&rft.epage=i859&rft.pages=i859-i859&rft.issn=1756-1833&rft.eissn=1756-1833&rft_id=info:doi/10.1136/bmj.i859&rft_dat=%3Cproquest_pubme%3E4008212051%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b428t-f7c5fa484653af1ec7656bb6fa36dd8c56d2062c05468e8e55b388e3c5240e2a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1777833168&rft_id=info:pmid/27030675&rfr_iscdi=true |